Technologies

Innovations

4Cell Therapies S.A. develops CAR-T technologies aimed at treating tumours, based on proprietary, original solutions. Research and development works are realized in Warsaw and Gliwice by young Polish scientists with international experience.

Products

Products of 4Cell Therapies S.A. are created on the basis of licences acquired from companies and institutions from all over the world, especially the USA and Canada.

Partners

Among partners of the Company in Poland, we count the National Research Institute of Oncology, the Medical University of Warsaw and the Silesian University of Technology. These institutions – within the framework of concluded agreements – support pre-clinical, clinical and infrastructural development of projects realized by 4Cell Therapies S.A.

Three domains of activity

The Company realizes research & development projects in three domains:

1

CAR-T therapies aimed at treating hematologic malignancies, especially multiple myeloma - BCMA-CAR-T.
Hematologic malignancies constitute 4% of all malignant tumours. The therapy is developed in cooperation with ProMab Biotechnologies Inc. (CA, USA) and the National Research Institute of Oncology in Gliwice.

2

CAR-T therapies aimed at treating solid tumours, especially pancreatic carcinoma, gastric and colorectal carcinoma - CEACAM6-CAR-T. Solid tumours constitute 96% of all malignant tumours. As the company holds solutions that have proved to be highly effective in animal models of human pancreatic carcinoma, 4Cell Therapies S.A. has a chance to take the position of the world leader in this domain. This technology is developed in cooperation with the National Research Council of Canada (Ottawa, Canada).

3

Innovative infrastructural solutions and automation of CAR-T production on industrial scale. The company creates proprietary, innovative infrastructure for CAR-T production in Gliwice and does so in a consortium with the Silesian University of Technology – an academic partner with ample experience in implementation of original industrial solutions in business practice.

These projects are financed from Company's own means and co-financed from public sources.